The Biogen/Eisai news isn't a clear victory. Lots of questions that will await the reveal of the full trial data. It will take more than today's report to prove the amyloid hypothesis. Here is a more balanced Endpoints news article on today's BAN2401 news.
https://endpts.com/that-alzheimers-drug-that-flunked-a-phii-on-second-look-biogen-eisai-say-its-a-winner/